'Profound' Results With Ibrutinib Add-On in Mantle Cell Lymp

Results from the phase 3 SHINE trial show that adding ibrutinib to standard therapy delays progression by 50% in older patients with mantle cell lymphoma.

Related Keywords

Houston , Texas , United States , American , Michael Wang , Julier Gralow , Abbvie Company , Genentech , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Genomic Health , Novartis , Astrazeneca , Janssen Pharmaceuticals , Cancer Center , American Society , Clinical Oncology , New England Journal , First Line Use , Puma Biotechnology , Mantle Cell Lymphoma , Hematology , Lymphoma , Malignant Lymphoma , Chemotherapy , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , Ituximab , U11248 , Unitinib ,